Try
GILEAD SCIENCES, INC.
GILDUnited States
76 filed reports · 597 financial concepts · 41 earnings calls · 11 media appearances
Filed reports
76 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 366 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 35 | 374 | Dec 2017 to Jun 2026 |
| Quarterly · 10-QSEC EDGAR | 31 | 9,617 | Jun 2016 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 8,088 | Dec 2016 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 596 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 4, 2026 | 8 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 7, 2026 | 6 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 436 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 24, 2026 | 1,541 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 10, 2026 | 4 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 7, 2025 | 434 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 30, 2025 | 8 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 278 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Aug 7, 2025 | 10 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 7, 2025 | 261 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | Apr 24, 2025 | 10 | Open |
Financial data
597 concepts · 18,079 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial574 concepts · 11,748 facts · Dec 2014 to Jul 2026
- Total73 · Dec 2015 to Jun 2026
- Net income loss58 · Dec 2014 to Jun 2026
- Revenue58 · Dec 2014 to Jun 2026
- Comprehensive income net of tax57 · Dec 2014 to Jun 2026
- Costs and expenses57 · Dec 2014 to Jun 2026
- Income tax expense benefit57 · Dec 2014 to Jun 2026
- Incremental common shares attributable to share based payment arrangements57 · Dec 2014 to Jun 2026
- Nonoperating income expense57 · Dec 2014 to Jun 2026
- Operating income loss57 · Dec 2014 to Jun 2026
- Selling general and administrative expense57 · Dec 2014 to Jun 2026
- Adjustment for amortization56 · Dec 2014 to Jun 2026
- Depreciation56 · Dec 2014 to Jun 2026
- Increase decrease in accounts payable56 · Dec 2014 to Jun 2026
- Increase decrease in accounts receivable56 · Dec 2014 to Jun 2026
- Increase decrease in accrued liabilities56 · Dec 2014 to Jun 2026
- Increase decrease in inventories56 · Dec 2014 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets56 · Dec 2014 to Jun 2026
- Net cash provided by used in financing activities56 · Dec 2014 to Jun 2026
- Net cash provided by used in investing activities56 · Dec 2014 to Jun 2026
- Net cash provided by used in operating activities56 · Dec 2014 to Jun 2026
- Payments for repurchase of common stock56 · Dec 2014 to Jun 2026
- Payments of dividends56 · Dec 2014 to Jun 2026
- Proceeds from issuance of common stock56 · Dec 2014 to Jun 2026
- Proceeds from maturities prepayments and calls of available for sale securities56 · Dec 2014 to Jun 2026
Product2 concepts · 5,707 facts · Dec 2014 to Jun 2026
- Revenue5,700 · Dec 2014 to Jun 2026
- Contract with customer performance obligation satisfied in previous period7 · Jun 2018 to Sep 2021
Guidance14 concepts · 374 facts · Feb 2018 to Aug 2026
- EPS (Diluted) Guidance50 · Feb 2020 to Aug 2026
- Effective Tax Rate Guidance46 · Feb 2018 to Oct 2025
- Revenue Guidance44 · Feb 2018 to Aug 2026
- EPS (Diluted) Guidance (Adjusted (non-GAAP))32 · Feb 2020 to Aug 2026
- Gross Margin Guidance30 · Feb 2018 to May 2026
- Gross Margin Guidance (Product; Adjusted (non-GAAP))30 · Feb 2020 to Apr 2024
- Operating Income Guidance30 · Feb 2020 to Aug 2025
- Gross Margin Guidance (product)26 · Feb 2020 to Apr 2024
- Effective Tax Rate Guidance (Adjusted (non-GAAP))24 · Feb 2020 to Apr 2024
- Operating Income Guidance (Adjusted (non-GAAP))24 · Feb 2020 to Apr 2024
- Revenue Guidance (Net product revenues)22 · Feb 2020 to Feb 2024
- Revenue Guidance (product sales, excluding Veklury)8 · Apr 2022 to Feb 2024
- Revenue Guidance (excluding Veklury)6 · Feb 2022 to Aug 2026
- Revenue Guidance (excluding Veklury sales; Adjusted (non-GAAP))2 · Apr 2021
Geography4 concepts · 208 facts · Dec 2014 to Jun 2026
- Revenue162 · Dec 2014 to Jun 2026
- Revenue (excluding assessed tax)33 · Jun 2017 to Dec 2019
- Property, Plant & Equipment, Net11 · Dec 2020 to Dec 2025
- Accounts Receivable, Net2 · Jun 2016 to Sep 2016
Segment3 concepts · 42 facts · Dec 2022 to Jun 2026
- General and administrative expense (US GAAP)14 · Dec 2022 to Jun 2026
- Selling and marketing expense (US GAAP)14 · Dec 2022 to Jun 2026
- Selling general and administrative expense14 · Dec 2022 to Jun 2026
Segments
5,957 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis61 members · 5,254 facts
- HIV Products Symtuza Revenue Share188 · Dec 2016 to Jun 2026
- Other Products Am Bisome188 · Dec 2016 to Jun 2026
- Product188 · Dec 2016 to Jun 2026
- Royalty Contract And Other187 · Dec 2016 to Jun 2026
- Other Products Other182 · Dec 2016 to Jun 2026
- HIV Products Biktarvy176 · Dec 2016 to Jun 2026
- HIV Products Descovy176 · Dec 2016 to Jun 2026
- HIV Products Genvoya176 · Dec 2016 to Jun 2026
- HIV Products Odefsey176 · Dec 2016 to Jun 2026
- Other Products Yescarta176 · Dec 2016 to Jun 2026
- Liver Disease Products Sofosbuvir Velpatasvir172 · Dec 2017 to Jun 2026
- Veklury144 · Dec 2018 to Jun 2026
- Other Products Letairis140 · Dec 2016 to Dec 2023
- Products Other HIV140 · Dec 2016 to Dec 2023
- Cell Therapy Products Tecartus136 · Dec 2018 to Jun 2026
- Cell Therapy Products Total Cell Therapy Product Sales136 · Dec 2018 to Jun 2026
- HIV Product Sales136 · Dec 2018 to Jun 2026
- Other Products Total Other Product Sales136 · Dec 2018 to Jun 2026
- Trodelvy132 · Dec 2019 to Jun 2026
- HIV Products Complera Eviplera128 · Dec 2016 to Dec 2023
- HIV Products Truvada128 · Dec 2016 to Dec 2023
- HIV Products Stribild127 · Dec 2016 to Dec 2023
- HCV Products Ledipasvir Sofosbuvir123 · Dec 2017 to Dec 2023
- Other Products Ranexa100 · Dec 2016 to Dec 2021
- Other Products Zydelig100 · Dec 2016 to Dec 2021
- Liver Disease92 · Dec 2021 to Jun 2026
- Oncology Product92 · Dec 2021 to Jun 2026
- HCV Product Sales88 · Dec 2018 to Dec 2023
- HIV Products Atripla88 · Dec 2016 to Dec 2021
- Hepatitis B Virus Hepatitis Delta Virus Product84 · Dec 2019 to Dec 2023
- Hepatitis B Virus Hepatitis Delta Virus Product Other84 · Dec 2019 to Dec 2023
- Hepatitis B Virus Hepatitis Delta Virus Product Vemlidy84 · Dec 2019 to Dec 2023
- Hepatitis B Virus Hepatitis Delta Virus Product Viread84 · Dec 2019 to Dec 2023
- HIV Products Other HIV72 · Dec 2022 to Jun 2026
- Liver Disease Products Other Liver Disease72 · Dec 2022 to Jun 2026
- Liver Disease Products Vemlidy72 · Dec 2022 to Jun 2026
- Other Products Vemlidy68 · Dec 2016 to Dec 2020
- Other Products Viread68 · Dec 2016 to Dec 2020
- HCV Products Vosevi60 · Dec 2016 to Sep 2020
- Other Hepatitis C Virus Products48 · Mar 2020 to Sep 2023
- Other HCV24 · Dec 2018 to Dec 2023
- Antiviral Products Atripla16 · Jun 2017 to Sep 2018
- Antiviral Products Biktarvy16 · Jun 2017 to Sep 2018
- Antiviral Products Complera Eviplera16 · Jun 2017 to Sep 2018
- Antiviral Products Descovy16 · Jun 2017 to Sep 2018
- Antiviral Products Epclusa16 · Jun 2017 to Sep 2018
- Antiviral Products Genvoya16 · Jun 2017 to Sep 2018
- Antiviral Products Harvoni16 · Jun 2017 to Sep 2018
- Antiviral Products Odefsey16 · Jun 2017 to Sep 2018
- Antiviral Products Stribild16 · Jun 2017 to Sep 2018
- Antiviral Products Truvada16 · Jun 2017 to Sep 2018
- Antiviral Products Vemlidy16 · Jun 2017 to Sep 2018
- Antiviral Products Viread16 · Jun 2017 to Sep 2018
- Antiviral Products Vosevi16 · Jun 2017 to Sep 2018
- HIV Products Yeztugo16 · Mar 2025 to Jun 2026
- Liver Disease Products Livdelzi16 · Mar 2025 to Jun 2026
- COVID19 Products Trodelvy12 · Dec 2018 to Dec 2020
- HCV Products Epclusa12 · Dec 2016 to Dec 2018
- HCV Products Harvoni12 · Dec 2016 to Dec 2018
- Royalty6 · Mar 2020 to Sep 2021
- Royalties For Licenses Of Intellectual Property1 · Jun 2018
Product or serviceus-gaap:ProductOrServiceAxis41 members · 453 facts
- Ambisome15 · Dec 2014 to Dec 2017
- Antiviral Products15 · Dec 2014 to Dec 2017
- Atripla15 · Dec 2014 to Dec 2017
- Complera Eviplera15 · Dec 2014 to Dec 2017
- Descovy15 · Dec 2014 to Dec 2017
- Epclusa15 · Dec 2014 to Dec 2017
- Genvoya15 · Dec 2014 to Dec 2017
- Harvoni15 · Dec 2014 to Dec 2017
- Letairis15 · Dec 2014 to Dec 2017
- Odefsey15 · Dec 2014 to Dec 2017
- Otherantiviralproducts15 · Dec 2014 to Dec 2017
- Other Products15 · Dec 2014 to Dec 2017
- Ranexa15 · Dec 2014 to Dec 2017
- Sovaldi15 · Dec 2014 to Dec 2017
- Stribild15 · Dec 2014 to Dec 2017
- Truvada15 · Dec 2014 to Dec 2017
- Viread15 · Dec 2014 to Dec 2017
- Zydelig15 · Dec 2014 to Dec 2017
- Antiviral Products And Other Products8 · Mar 2017 to Mar 2018
- Antiviral Products Atripla8 · Mar 2017 to Mar 2018
- Antiviral Products Biktarvy8 · Mar 2017 to Mar 2018
- Antiviral Products Complera Eviplera8 · Mar 2017 to Mar 2018
- Antiviral Products Descovy8 · Mar 2017 to Mar 2018
- Antiviral Products Epclusa8 · Mar 2017 to Mar 2018
- Antiviral Products Genvoya8 · Mar 2017 to Mar 2018
- Antiviral Products Harvoni8 · Mar 2017 to Mar 2018
- Antiviral Products Odefsey8 · Mar 2017 to Mar 2018
- Antiviral Products Other8 · Mar 2017 to Mar 2018
- Antiviral Products Stribild8 · Mar 2017 to Mar 2018
- Antiviral Products Truvada8 · Mar 2017 to Mar 2018
- Antiviral Products Vemlidy8 · Mar 2017 to Mar 2018
- Antiviral Products Viread8 · Mar 2017 to Mar 2018
- Antiviral Products Vosevi8 · Mar 2017 to Mar 2018
- Other Products Am Bisome8 · Mar 2017 to Mar 2018
- Other Products Letairis8 · Mar 2017 to Mar 2018
- Other Products Other8 · Mar 2017 to Mar 2018
- Other Products Ranexa8 · Mar 2017 to Mar 2018
- Other Products Yescarta8 · Mar 2017 to Mar 2018
- Other Products Zydelig8 · Mar 2017 to Mar 2018
- Royalty Contract And Other8 · Mar 2017 to Mar 2018
- Vosevi7 · Dec 2015 to Dec 2017
Statement geographicalsrt:StatementGeographicalAxis7 members · 185 facts
- Europe47 · Dec 2016 to Jun 2026
- Rest Of World47 · Dec 2016 to Jun 2026
- US47 · Dec 2016 to Jun 2026
- Us17 · Jun 2017 to Dec 2025
- Rest of world11 · Jun 2017 to Dec 2019
- Europe11 · Jun 2017 to Dec 2019
- Non us5 · Dec 2020 to Dec 2025
Statement business segments1 member · 42 facts
- Reportable42 · Dec 2022 to Jun 2026
Statement geographicalus-gaap:StatementGeographicalAxis6 members · 23 facts
- Europe6 · Dec 2014 to Mar 2018
- US6 · Dec 2014 to Mar 2018
- Other Countries4 · Dec 2014 to Dec 2017
- JP3 · Dec 2014 to Dec 2016
- Southern europe2 · Jun 2016 to Sep 2016
- Rest Of World2 · Mar 2017 to Mar 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary189 claims from 8 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary187 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes14 claims from 1 reports · Dec 2025
- Risk factors49 risks from 2 annual reports · 2024 to 2025
Earnings calls
41 calls · Jul 2016 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 4, 2026
- FY2026 Q1May 7, 2026
- FY2025 Q4Feb 10, 2026
- FY2025 Q3Oct 30, 2025
- FY2025 Q2Aug 7, 2025
- FY2025 Q1Apr 24, 2025
- FY2024 Q4Feb 11, 2025
- FY2024 Q3Nov 6, 2024
- FY2024 Q2Aug 8, 2024
- FY2024 Q1Apr 25, 2024
- FY2023 Q4Feb 6, 2024
- FY2023 Q3Nov 7, 2023
- FY2023 Q2Aug 3, 2023
- FY2023 Q1Apr 27, 2023
- FY2022 Q4Feb 2, 2023
- FY2022 Q3Oct 27, 2022
Executive media
11 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- TV interviews6 · Jan 2020 to Jan 2026
- Other appearances4 · May 2020 to May 2026
- Conference talks1 · May 2021
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.